Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model

Myung-Hee Moon, Jae-Kyo Jeong,
Ju-Hee Lee, Yang-Gyu Park, You-Jin Lee,
Jae-Won Seol and Sang-Youel Park[1]

Biosafty Research Institute
College of Veterinary Medicine
Chonbuk National University
Jeonju 561-756, Korea
[1]Corresponding author: Tel, 82-63-270-3886;
Fax, 82-63-270-3780; E-mail, sypark@chonbuk.ac.kr
http://dx.doi.org/10.3858/emm.2012.44.10.069

Abstract

Higher levels of body fat are associated with an increased risk for development numerous adverse health conditions. FTY720 is an immune modulator and a synthetic analogue of sphingosine 1-phosphate (S1P), activated S1P receptors and is effective in experimental models of transplantation and auto-immunity. Whereas immune modulation by FTY720 has been extensively studied, other actions of FTY720 are not well understood. Here we describe a novel role of FTY720 in the prevention of obesity, involving the regulation of adipogenesis and lipolysis *in vivo* and *in vitro*. Male C57B/6J mice were fed a standard diet or a high fat diet (HFD) without or with FTY720 (0.04 mg/kg, twice a week) for 6 weeks. The HFD induced an accumulation of large adipocytes, down-regulation of phosphorylated AMP-activated protein kinase α (p-AMPKα) and Akt (p-Akt); down-regulation of hormone- sensitive lipase (HSL), adipose triglyceride lipase (ATGL) and perilipin mRNA as well as up-regulation of phosphorylated HSL (p-HSL, Ser563) and glycogen synthase kinase 3 α/β (p-GSK3α/β). All these effects were blunted by FTY720 treatment, which inhibited adipogenesis and promoted lipolysis. Also, FTY720 significantly decreased lipid accumulation in maturing preadipocytes. FTY720 down-regulated the transcriptional levels of the PPARγ, C/EBPα and adiponectin, which are markers of adipogenic differentiation. FTY720 significantly increased the release of glycerol and the expression of the HSL, ATGL and perilipin, which are regulators of lipolysis. These results show that FTY720 prevented obesity by modulating adipogenesis and lipolysis, and suggest that FTY720 is used for the treatment of obesity.

Keywords: adipocyte; adipogenesis; antiobesity; FTY720; lipolysis

Introduction

An imbalance between energy intake and expenditure can result in excess triacylglycerol accumulation in adipose tissue, resulting in obesity (Duncan et al., 2007). In morbid obesity an increased adipocyte number (hyperplasia) may occur through adipocyte differentiation of precursor cells present in adipose tissue (Ntambi and Kim, 2000; Rosen and MacDougald, 2006). However, obesity is largely attributed to adipocyte hypertrophy that occurs when triacylglycerol synthesis exceeds breakdown (lipolysis), resulting in elevated triacylglycerol storage (Duncan et al., 2007; Jaworski et al., 2007). Indeed, unlike triacylglycerol synthesis (Dircks and Sul, 1999; Jaworski et al., 2009) that occurs at high levels in other tissues, lipolysis for the liberation of fatty acids that can then be used as an energy source by other tissues is unique to adipocytes (Duncan et al., 2007). Thus, lipolysis and hyperplasia of adipocytes might be important factors in the development of obesity.

Lipolysis is one of the most important metabolic pathways regulating energy homeostasis and the pathogenesis of obesity (Zimmermann et al., 2004). Lipolysis is governed by two major enzymes that are hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) (Bézaire et al., 2009). ATGL initiates lipolysis by cleaving the first FA from

triglyceride (TG) and then HSL act on diacyglycerol (DAG), releasing two additional FAs and one glycerol molecule (Gaidhu *et al.*, 2010). Whereas HSL is present in the cytosol, ATGL is localized in the cytosol and also on lipid droplets (Zimmermann *et al.*, 2004; Lasa *et al.*, 2012).

Adipocytes are derived from mesenchymal stem cells, which have the potential to differentiate into myoblasts, chondroblasts, osteoblasts or adipocytes (Rayalam *et al.*, 2008). Adipogenesis has been investigated extensively using 3T3-L1 cells. Adipocyte differentiation involves an elaborate network of transcription factors that regulate the expression of numerous genes responsible for the phenotype of mature adipocytes (Lee *et al.*, 2009). Among the various transcription factors that promote preadipocyte differentiation and influence adipogenesis, peroxisome proliferator-activated receptor gamma (PPARγ) has been termed the "master regulator of adipogenesis" (Tontonoz and Spiegelman, 2008; Wakabayashi *et al.*, 2009). Other adipogenic transcription factors include the CCAAT/enhancer binding proteins (C/EBPα) (Nerurkar *et al.*, 2010). They are necessary for the expression of adipocyte-specific genes, such as adiponectin (Xing *et al.*, 2010).

Akt (protein kinase B, PKB), a PH domain containing serine/threonine kinase, regulates growth factor signaling to stimulate glucose uptake, glycogen synthesis (Cross *et al.*, 1995) and protein synthesis by influencing the glycogen synthase kinase 3 (GSK3)α/β and tuberous sclerosis complex 2 (TSC2)-mTOR signaling pathways. Increased protein translation following Akt activation elicits skeletal muscle hypertrophy (Rommel *et al.*, 2001) and augments hepatic fatty acid oxidation with reduced fat accumulation (Izumiya *et al.*, 2008). GSK3β, which influences insulin resistance, is phosphorylated and inhibited by Akt (Cross *et al.*, 1995). Akt and GSK3β activity are reciprocally regulated in insulin resistance and obesity. Akt/mTOR activity is decreased (Shao *et al.*, 2000; Funai *et al.*, 2006) and GSK3β increased (Kaidanovich and Eldar-Finkelman, 2002) in insulin-resistant tissues of aging and obese mice (Chakraborty *et al.*, 2010).

AMP-activated protein kinase (AMPK) activation leads to increased fat oxidation by the upregulation of the transcription factor NRF-1, which stimulates mitochondrial biogenesis and inhibits both lipolysis and lipogenesis, affecting directly the enzymes engaged in lipid metabolism and down-regulating PPARγ expression (Moreno-Navarrete *et al.*, 2009).

FTY720 (2-amino-2-[2-(4-*n*-octylphenyl)ethyl]-1, 3-propanediol hydrochloride) is synthetically derived from myriocin (ISP-1), a metabolite isolated from ascomycete, *Isaria sinclarii* (Kiuchi *et al.*, 2000). FTY720 is undergoing clinical trials for the treatment of immunologic disorders (Mansoor and Melendez, 2008). FTY720-P is an analog of sphingosine 1-phosphate (S1P) that mediates its immunomodulatory effects primarily through G protein-coupled S1P receptors (Spiegel and Milstien, 2003; Hannun and Obeid, 2008). It is a prodrug phosphorylated by type 2 sphingosine kinase to form FTY720-phosphate (FTY720-P) (Kihara and Igarashi, 2008). The S1P$_1$ receptor regulates the egress of lymphocytes from secondary lymphoid organs. By inducing the internalization and degradation of the S1P$_1$ receptor, FTY720-P reduces circulating lymphocyte counts, and is therefore considered a promising therapy for immune disorders (Takabe *et al.*, 2008). However, other functions of FTY720 excluding immune modulation remain largely unknown. Recently, FTY720 was found to be able to prevent high-fat diet (HFD-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice (Kendall and Hupfeld, 2008). However, this previous study mainly focused on the effect of FTY720 on lymphocytes sequestration. The effect of FTY720 on adipocytes has not been studied, especially on adipogenesis and lipolysis, which are important on obesity development.

Investigation of the direct effect of FTY720 on adipocytes will provide some novel insights for additional inhibitory mechanism of FTY720 on obesity. We report that administration of FTY720 prevents obesity from high fat feeding by not only regulating lipolysis through HSL activation but also inhibiting adipogenesis *via* phosphorylation of Akt.

Results

FTY720 administration mice are resistant to obesity

In this study, obesity was induced in normal mice by feeding a HFD for 10 weeks. After 3 weeks, mice fed the SD weighted 25.7 $\pm$ 0.6 *g* (*n* = 5), while control mice fed the HFD (HFD-CON) weighted 31.4 $\pm$ 2 *g* (*n* = 6). The respective weights at 8 weeks were 31.3 $\pm$ 1.5 *g* (*n* = 6) and 42.4 $\pm$ 1.7 *g* (*n* = 6). Compared with mice fed the SD, mice fed the HFD increased their body weight by 24.6% after 3 weeks of feeding and became 51.1% heavier after 8 weeks of feeding (Figures 1A and 1B). Parallel to the body weight change, the weights of white adipose tissue (WAT) were significantly higher in obese mice than in normal mice at the end of 16 weeks (data not shown). FTY720 administration to mice fed the HFD (HFD-FTY720) effectively suppressed the increase in body weight compared with HFD-CON mice. After one week of injection, HFD-FTY720 mice weighted 33.8 $\pm$ 1.3 *g* (*n* = 6), while HFD-CON mice weighted 37.4 $\pm$ 1.9 *g* (*n* = 6). Compared with HFD mice,

Figure 1. FTY720 administration mice are resistant to obesity. (A) Gross appearance of standard diet (*n* = 5, SD) and high fat-diet (*n* = 6, HFD) fed mice. (B) Time course of body weights over 15 weeks in mice fed a SD and HFD. (C) Gross appearance of HFD controls (*n* = 6, CON), PBS-treated (*n* = 6, PBS) and FTY720-treated (*n* = 6, FTY) obese mice. (D) Time course of body weights over 15 weeks in mice fed with HFD and intraperitoneally injected with none (*n* = 6, CON), PBS-treated (*n* = 6, PBS) and FTY720-treated (*n* = 6, FTY). (E, F) Average body weights (E), epididymal fat pad weights (F) and organ weights (G) of mice at 15 weeks. (H, I) Representative images (H) of hematoxylin and eosin-stained sections of gonadal WAT and adipocyte cell size (I) in gonadal WAT. (J, K) Body fat composition of HFD controls (*n* = 6, CON), PBS-treated (*n* = 6, PBS) and FTY720-treated (*n* = 6, FTY) obese mice was calculated percent of CON. Data are expressed as the means ± SD for 6 mice. *$P < 0.05$; and **$P < 0.01$, significant differences between HFD control and each treatment group; ##$P < 0.01$, significant differences between PBS treatment group and FTY720 treatment group.

Figure 2. FTY720 phosphate (FTY-p) decreases lipid droplets during the differentiation of 3T3-L1 preadipocytes. (A) Preadipocytes were induced to differentiate with FTY-p of increasing concentrations for 6 days. The AdipoRed assays were performed on day 6 and were photographed with a light microscope ($\times$ 200). (B) Fluorescence was measured with an excitation wavelength of 485 nm and an emission wavelength of 572 nm. Bar graph indicates the mean $\pm$ S. E. M. (n = 3). The experiments were repeatedly performed to confirm the results. The data were analyzed using analysis of variance (ANOVA) and Duncan multiple range test ($P < 0.05$). Means sharing a common alphabetical symbol do not differ significantly. (C-E) Preadipocytes were induced to differentiate with FTY-p (1 μM) and harvested at day 7 during the differentiation period. The mRNA expression of PPARγ (C), C/EBPα (D) and adiponectin (E) was analyzed by real-time RT-PCR. Values are mean $\pm$ S. E. M. of data from three separate experiments (n = 3); each experiment was performed in triplicate. The data were analyzed using analysis of variance (ANOVA) and Duncan multiple range test ($P < 0.05$). Means sharing a common alphabetical symbol do not differ significantly. (F) Preadipocytes were induced to differentiate with or without FTY-p 0.1 and 1 μM for 2 days. At day 2, the protein levels of p-Akt were analyzed by Western blot. The experiments were repeatedly performed to confirm the results.

HFD-FTY720 mice displayed an 11% reduced body weight 1 week after the administration of FTY720. This ratio was maintained until the end of the experiment (Figures 1C and 1D). The lower body weight of the mice administered FTY720 was largely accounted for by a reduction in WAT weight (Figures 1F and 1G). At 16-weeks-of-age, HFD-FTY mice had effectively smaller WAT depots compared to HFD mice, with a combined WAT depot weight that was 20% lower (Figure 1F). Body composition analysis indicated that FTY treatment decreased triacylglycerol content (Figure 1H). Histological analysis showed that the gonadal WAT from HFD-CON contained significantly large adipocytes (Figures 1I-1K, $P < 0.01$) compared with SD, but FTY720 mice displayed considerably smaller adipocytes compared with those of HFD-CON mice (Figures 1I-1K).

FTY720 inhibits adipocyte differentiation of 3T3-L1 cells

A decrease in adipose tissue mass can be a result of a decrease in adipocyte size and/or number due to reduction of adipocyte differentiation (Gregoire *et al*., 1998). Also, FTY720 is phosphorylated *in vivo* by sphingosine kinase 2 to become the active drug metabolite (S)-FTY720-phosphate (FTY-p) and only the (S)-phosphorylated form of FTY720 is capable of activating S1P receptors *in vitro* (Brinkmann *et al*., 2004; Valentine *et al*., 2010). Therefore, we studied the influence of FTY-p on adipocyte differentiation in the 3T3-L1 cells. When 3T3-L1 cells were allowed to differentiate over 6 days in the presence of increasing concentrations of FTY-p in the adipogenic medium, a reduction in TG accumulation was observed (Figures 2A and 2B). The effect of FTY-p was significantly detected at 0.1 μM and was maximal at 1 μM.

To confirm the anti-adipogenic differentiation of FTY-p, the mRNA levels of biochemical markers of differentiation (PPARγ, C/EBPα and adiponectin) were determined (Figures 2C-2E). When the 3T3-L1 preadipocytes were differentiated with MDI treatment, the mRNA levels of the adipogenic markers of differentiation increased compared to the control. However, FTY-p treatment led to a significant reduction in the mRNA level of PPARγ, C/EBPα and adiponectin (Figures 2C-2E). The evidence was consistent with an influence of FTY720 on adipocyte differentiation.

Besides altering insulin sensitivity, Akt and its downstream effectors can reduce fat accumulation by reducing adipogenesis *via* GSK3β (Ross *et al*.,

Figure 3. FTY720 induces Akt phosphorylation and inhibits the activation of GSK-3α/β. (A) Western blot analysis for p-Akt (Ser 473) (Upper panel) and p-GSK-3α/β (Tyr279/216) (middle panel) protein in WAT of standard diet (*n* = 3, SD), high fat-diet (*n* = 5, HFD CON) and FTY720-treated obese mice (*n* = 5, HFD FTY720). (B) Levels of p-Akt (Ser 473) and p-GSK-3α/β (Tyr279/216) were normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using student's t-test. **$P < 0.01$, significant differences between SD and each treatment group; ##$P < 0.01$, significant differences between HFD-CON and HFD- FTY720 group.

2000; Chakraborty *et al.*, 2010). To gain insight into the molecular mechanisms responsible for the observed biological effects of FTY-p, the ability of the FTY-p to inactivate Akt was then examined. As illustrated in Figure 3F, MDI containing adipocyte differentiation cocktail decreased the phosphorylation of Akt Ser 473. However, the incorporation of 1 μM FTY-p increased the phosphorylation of Akt (Ser 473). These results showed that FTY-p regulated the phosphorylation of Akt, and so had an anti-adipogenic effect *in vitro*.

FTY720 reduces fat accumulation *via* up-regulation of p-Akt (Ser473) and down-regulation of p-GSK3α/β (Tyr279/216), as well as up-regulation of p-AMPKα (Thr 172)

As mentioned above, phosphorylation of Akt is important *in vivo* for improving the insulin sensitivity and exerting an anti-obesity effect through a reduction in adipogenesis *via* GSK3β. Akt-mediated inhibition of GSK3β inhibits adipogenesis (Ross *et al.*, 2000; Tang *et al.*, 2005). Therefore, we detected that the levels of p-Akt (Ser 473) and p-GSK3α/β (Tyr279/216) in HFD-FTY compared with SD and HFD-CON (Figure 3). In mice fed the SD, the level of phosphorylation of Akt (Ser 473) was high, but obesity was declined. The administration of FTY720


Figure 4. FTY720 induces AMPK phosphorylation *in vivo* as well as *in vitro*. (A) Western blot analysis for p-AMPK (Thr 172) protein in WAT of standard diet (*n* = 4, SD), high fat-diet (*n* = 5, HFD CON) and FTY720-treated obese mice (*n* = 5, HFD FTY720). (B) Levels of p-AMPK (Thr 172) were normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using student's t-test. **$P < 0.01$, significant differences between SD and each treatment group; ##$P < 0.01$, significant differences between HFD-CON and HFD- FTY720 group (C) Preadipocytes were induced to differentiate with or without FTY-p 0.1, 1 and 10 μM for 4, 12 and 24 h. At indicated hours, the protein levels of p-AMPK were analyzed by Western blot. The experiments were repeatedly performed to confirm the results. (D) Level of p-AMPK was normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using Student's t-test. **$P < 0.01$, significant differences between control and each treatment group.

showed a dramatic rise of the activation of Akt. Reciprocally, the phosphorylation of GSK3α/β (Tyr279/216) was decreased in SD and HFD induced an incremental increase, but FTY720 tended to decrease it (Figure 3).

Also, phosphorylation of AMPK is pivotal for increasing energy expenditures such as fatty acid oxidation and for inhibiting energy accumulation such as lipogenesis and adipogenic differentiation.

The role of AMPK in adipogenesis is not entirely clear, but several AMPK-activating molecules have anti-adipogenic effects *via* MCE inhibition and down-regulation of adipogenic transcriptional pathways (Vingtdeux *et al.*, 2011). Therefore, we measured the expression of p-AMPKα (Thr 172) in HFD-FTY compared with SD and HFD-CON (Figures 4A and 4B). In mice fed with SD, the level of p-AMPKα (Thr 172) was high, but obesity attenuated it. FTY720 showed a significant rise of the phosphorylation of AMPK. In 3T3-L1 cells, FTY720-p increased the level of phosphorylation of AMPK in a dose-dependent manner as well (Figures 4C and 4D).

These observations supported the view that reduced fat accumulation in FTY720 treated mice is a result of reduced adipogenesis through AMPK and Akt- GSK3α/β pathway.

FTY720 enhances fat breakdown through up-regulation of HSL, ATGL, perilipin and phosphorylation of HSL

Lipolysis in the WAT of humans and rodents is regulated by ATGL, HSL and perilipin (Gaidhu *et al.*, 2010; Sawada *et al.*, 2010). To investigate whether the markedly decreased adiposity observed in HFD-FTY mice was the result of increased lipolysis, we measured the expression of HSL, ATGL and perilipin in gonadal WAT of SD, HFD-CON and HFD-FTY mice. When compared with the WAT of SD, HFD feeding caused significant down-regulations of HSL, ATGL and perilipin mRNA levels (Figures 5A-5C), but FTY720 treatment increased the mRNA levels of HSL, ATGL and perilipin (Figures 5A-5C). The activity of HSL is regulated by both phosphorylation and translocation to the lipid droplet. PKA phosphorylates HSL at Ser 563 (Yin *et al.*, 2003; Zhou *et al.*, 2011). In accordance with these studies, we detected the HSL phosphorylation at Ser 563 in WAT of SD and HFD-FTY mice (Figures 5D and 5E). In SD mice, HSL phosphorylation at Ser 563 in WAT was expressed at high levels, but HFD feeding markedly dropped the phosphorylation of HSL (Ser 563). The HSL phosphorylation at Ser 563 was considerably increased by the administration of FTY720 (Figures 5D and 5E). These results indicated that decreased adiposity in FTY720 treated mice is a result of enhanced lipolysis through the up-regulation of HSL, ATGL and perilipin, as well as phosphorylation of HSL.

FTY720-p increases adipocyte lipolysis of 3T3-L1 cells

To study the effect of FTY720-p on lipolysis *in vitro*, the differentiated adipocytes were incubated with


Figure 5. FTY720 up-regulates ATGL, HSL, perilipin gene expression as well as activation of HSL. (A-C) Relative mRNA levels were measured by RT-qPCR for the ATGL (A), HSL (B) and perilipin (C) genes from WAT of SD, HFD-CON and HFD-FTY mice. (D) Western blot analysis for the phosphorylation status of Ser 563 of HSL in WAT of SD ($n = 4$, SD), high fat-diet ($n = 5$, HFD CON) and FTY720-treated obese mice ($n = 5$, HFD FTY720). (E) Levels of p-HSL (Ser 563) was normalized to α-actin using densitometry. The experiments were repeatedly performed to confirm the results. The data were analyzed using student's t-test. **$P \leq 0.01$, significant differences between SD and each treatment group; ##$P < 0.01$, significant differences between HFD-CON and HFD- FTY720 group.

various concentrations of FTY720-p for 24 h or 1 μM of FTY720-p for various times, and the glycerol level was determined in the medium. FTY720-p treatment led to a significantly higher release of glycerol after the two treatment periods (12 h and 24 h) analyzed (Figure 6A). Also, FTY720-p substantially increased lipolysis in a dose-dependent fashion (Figure 6B).

To assess the effects of FTY720-p on major molecular mechanisms that regulate lipolysis *in vitro*, we examined the phosphorylation of HSL on key serine residues as well as the mRNA content of ATGL, HSL and perilipin. The differentiated adipocytes were incubated with 1 μM of FTY720-p for 12 h and 24 h, and the ATGL, HSL and perilipin mRNA levels were significantly increased (Figure 6C). After 24 h of treatment with 0.1 and 1 μM of FTY720-p, ATGL, HSL and perilipin expression were enhanced in

Figure 6. FTY720-p increases lipolysis as well as ATGL, HSL, perilipin mRNA levels and the activation of HSL in differentiated adipocytes. (A, B) Differentiated adipocytes were stimulated with indicated time (A) for 1 μM of FTY720-p or indicated concentrations (B) of FTY720-p for 24 h. The concentration of glycerol in the medium determined as described in Materials and Methods. (C, D) Differentiated adipocytes were stimulated with indicated time (C) with 1 μM FTY720-p or indicated concentrations (D) of FTY720-p for 24 h. Then, relative mRNA levels were measured by RT-qPCR for ATGL, HSL and perilipin. Bar graph indicates the mean ± S. E. M. (n = 3). *P < 0.05, **P < 0.01, significant differences between control and each treatment group; ##P < 0.01, significant differences between control and each treatment group; $$$P$ < 0.01, significant differences between control and each treatment group. (E) Western blot analysis for p-HSL (Ser 563) (Upper panel) and p-HSL (Ser 565) (middle panel) protein in differentiated adipocytes treated with 1 μM FTY720-p for 4 h, 24 h or 48 h. Methanol was used as vehicle control. (F) Levels of p-HSL (Ser 563) and p-HSL (Ser 565) were normalized to α-actin. The experiments were repeatedly performed to confirm the results. The data were analyzed using Student's t-test. *P < 0.05 and **P < 0.01, significant differences between S. E. M. and each treatment group; ##P < 0.01, significant differences between HFD-CON and HFD- FTY720 group.

differentiated adipocytes (Figure 6D).

HSL induces lipolysis after phosphorylation of serine residues 563, 659 and 660 (Anthonsen *et al.*, 1998; Shen *et al.*, 1998; Arner, 2005), leading to translocation of HSL to lipid droplets and to a marked enhancement of lipolysis. Phosphorylation of perilipin A, a protein associated with the lipid droplet, by protein kinase A (PKA) has also been demonstrated to be necessary for activation of HSL and for catecholamine-induced lipolysis to occur (Miyoshi *et al.*, 2006). Conversely, the cellular energy sensor AMPK has been demonstrated to phosphorylate serine-565 of HSL, which prevents PKA-mediated phosphorylation of this enzyme and impairs catecholamine-stimulated lipolysis (Garton *et al.*, 1989). While phosphorylation of HSL at Ser 563 was increased, phosphorylation of HSL at Ser 565 was dose-dependently decreased by FTY720-p

(Figures 6E and 6F). The effect of FTY720-p was significantly detected at 1 μM from 4 h and was prolonged to 48 h (Figures 6E and 6F). These results revealed the pro-lipolytic activity of FTY720-p *in vitro*.

Discussion

The data presented here show for the first time that FTY720 acts as an anti-obesity drug, which induces resistance to HFD-induced obesity and that the action of FTY720 is mediated by both anti-adipogenic differentiation and pro-lipolytic action. Administration of FTY720 to HFD-induced obese mice effectively reduced body weights as well as body fat mass by increasing anti-adipogenic action *via* the regulation of Akt-GSK 3α/β signaling and diminished lipolysis

via regulation of HSL. *in vitro*, treatment with exogenous FTY720-p effectively inhibited adipogenesis by down-regulating the expression of adipocyte specific differentiation markers. Moreover, treatment with exogenous FTY720-p significantly enhanced lipolysis by up-regulating the expression and phosphorylation of HSL, ATGL and perilipin.

Excessive adipose tissue accumulation is a result of an increase in both adipocyte number (hyperplasia) that occurs through adipocyte differentiation and adipocyte size (hypertrophy) that occurs when triacylglycerol synthesis exceeds breakdown (lipolysis). From this perspective, FTY720 might behave as a novel anti-obesity drug, because FTY720 effectively prevented HFD-induced obesity, both by blocking the adipocyte number and adipocyte size that through anti-adipogenic action and pro-lipolytic action, respectively.

FTY720 was originally derived as an immunomodulatory compound exerting beneficial effects in several animal models of chronic inflammation (Brinkmann *et al*., 2004; Chiba, 2005). A large number of preclinical studies have demonstrated the efficacy of FTY720 in models of organ transplantation, autoimmune disease and cancer (Brinkmann *et al*., 2004). FTY720 has focused over only immune suppression or proliferation, so we investigated other action of FTY720. Recently, consistent with our results (Figure 1), a new study found that FTY720 administration prevents HFD-induced weight gain, insulin resistance and adipose tissue inflammation (Kendall and Hupfeld, 2008). Moreover, this report revealed that resistance to HFD-induced obesity was caused by reduction of adipose tissue lymphocytes and macrophages, as well as the favoring of a CD11c-negative, anti-inflammatory macrophage phenotype, because adipose tissue activated macrophages and lymphocytes contribute to insulin resistance through the secretion of factors that impair insulin signaling (Shoelson *et al*., 2006; Kendall and Hupfeld, 2008). However, the study only clarified that FTY720 reduced adipose tissue lymphocytes and macrophages, as well as favoring a CD11c-negative, anti-inflammatory macrophage phenotype and focused on only immune modulating function of FTY720 (Kendall and Hupfeld, 2008). Furthermore, the administration dose of FTY720 (0.04 mg/kg twice per week) we used has been shown not to alter the leukocyte profile or the B-cell counts (Nofer *et al*., 2007). Our results presented here show for the first time previously unknown actions of FTY720, as a negative regulator of adipocyte differentiation (Figure 2) *via* the up-regulation of p-Akt (Figures 2F and 3) and a positive regulator of lipolysis (Figures 5 and 6) *in vivo* as well as *in vitro*.

Akt is related to lipogenesis. HFD-induced hepatic steatosis is correlated with decreased Akt phosphorylation upon insulin treatment (Pinto Lde *et al*., 2010). Skeletal muscle-specific overexpression of Akt 1 reduces fat accumulation while increasing fatty acid oxidation in the liver with less steatosis (Izumiya *et al*., 2008). Akt/mTOR-mediated skeletal muscle hypertrophy (Rommel *et al*., 2001) leads to increased insulin sensitivity (Izumiya *et al*., 2008), which may be physiologically associated with the alterations in insulin sensitivity of FTY720-treated mice. Moreover, GSK3β is adipogenic (Ross *et al*., 2000) so its inhibition in FTY720 administration mice may contribute to their leanness. Thus, the role of Akt in lipogenesis is complex and may reflect isoform- and tissue-specific effects.

The molecular machinery involved in triacylglycerol breakdown and fatty acid release works in an orderly and regulated fashion, conferring to WAT the capacity to respond to various feeding conditions and to the energy demands of the body (Gaidhu *et al*., 2010). Importantly, conditions that lead to overeating and obesity disrupt normal regulation of WAT lipolysis. In fact, basal lipolysis has repeatedly been reported as elevated, whereas catecholamine-induced lipolysis is suppressed in obese humans and rodents (Zimmermann *et al*., 2004; Jocken and Blaak, 2008). The classical mechanism to explain this condition is centered on the fact that the largely expanded WAT of obese subjects becomes resistant to insulin, impairing the major lipogenic and antilipolytic effects of this hormone (Roden, 2004; Zimmermann *et al*., 2004; Arner, 2005; Stumvoll *et al*., 2005; Gaidhu *et al*., 2010). In HFD-induced obese mice, HSL and perilipin content are severely reduced (Gaidhu *et al*., 2010). In line with this report, presently HSL and perilipin mRNA levels were seriously decreased and phosphorylation of HSL at Ser 563 was also markedly reduced in HFD-CON, but FTY720 reversed the content of HSL and perilipin and phosphorylation of HSL at Ser 563 in WAT (Figure 5). Also, FTY720 had effect on inducing lipolysis *in vitro*. FTY720-p treatment time- and dose-dependently increased glycerol release, lipolytic related gene expression and phosphorylation of HSL at Ser 563. Although increased lipolysis in HFD feeding led to the release of FFA to serum, resulting in insulin resistance terminally, other mouse models displaying increased lipolysis and decreased adipose tissue mass also reported unchanged or reduced serum non-esterified fatty acid (Martinez-Botas *et al*., 2000; Tansey *et al*., 2001; Lucas *et al*., 2003; Hertzel *et al*., 2006; Jaworski *et al*., 2009). Despite increased lipolysis resulted in ectopic triacylglycerol accumulation in the liver and skeletal muscle, oxygen consumption is increased and Ucp1, Dio2

and Ppard mRNA expression in WAT is substantially increased, suggesting higher oxidation and thermogenesis in WAT (Jaworski *et al.*, 2009). Moreover, AMPK has been shown to increase fatty acid oxidation in WAT. AMPK stimulates pathways, which increase fatty acid oxidation (Daval *et al.*, 2006). Presently, HFD decreased the phosphorylation of AMPK, but FTY720 increased the phosphorylation of AMPK in WAT (Figure 4). Therefore, we propose that FTY720 might increase energy production (glucose transport, fatty acid oxidation).

In conclusion, the results of this study show that exposure of HFD-induced obese mice to FTY720 inhibits the development of obesity. There are two suggested mechanisms of FTY720 to resistance to obesity. First, FTY720 inhibits adipogenesis *in vitro* as well as *in vivo*, as confirmed by a reduction in triglyceride accumulation, a reduction in the expression of adipocyte specific genes and regulating Akt pathways. Secondly, FTY720 enhances lipolysis *in vitro* as well as *in vivo*, as confirmed by an increase in glycerol release and lipolysis-associated gene expressions.

This is the first study to identify the anti-obesity action of FTY720 by the modulation of adipogenesis and lipolysis. These results suggest that FTY720 might be therapeutic for obesity.

Methods

Animals

All studies received approval from the Chonbuk University laboratory animal research center. We used mice on a pure C57BL/6J background. In total, 20 male and 5-week-old C57BL/6J mice initially weighing 20-22 g obtained from Samtako biokorea (Osan, Korea). The animal room was maintained at $23 \pm 1^{o}C$ with alternating 12-h light and dark cycles. After a 1-week acclimatization period, 20 mice were divided randomly into two groups. The normal group was fed with a standard diet (SD), whereas the model group was fed with a HFD. The SD was composed of 10 kcal% fat, 70 kcal% carbohydrates and 20 kcal% protein, whereas the HFD was composed of 45 kcal% fat, 35 kcal% carbohydrate, and 20 kcal% protein) (%kcal of total energy). After 3 weeks of feeding with the HFD, the resulting obese mice were subdivided randomly into three groups consisting of five mice each. One was an obese control model group. In the second group, mice were injected intraperitoneally (i.p.) with FTY720 (0.04 mg/kg in phosphate buffered saline (PBS) twice a week for 6 weeks). In both groups, body weight was measured weekly. The third group was administered the same volume (0.1 ml) of only the PBS vehicle. Whole body fat composition of live animals was determined after the treatment period using a Minispec nuclear magnetic resonance analyzer (Bruker Optics, Billerica, MA). The epididymal fat-pad samples were stored at $-70^{o}C$ until they were analyzed. All animal procedures were performed in accordance with the institutional guidelines for the Chonbuk University laboratory animal research center.

Reagents

FTY720 was purchased from Cayman Chemical (Ann Arbor, MI). FTY720 phosphate (FTY720-p) was purchased from Echelon Biosciences (Salt Lake City, UT). FTY720 was prepared as a 1 mg/ml solution in PBS. FTY720-p was prepared as a 2 mM solution in methanol and then further diluted in cell culture medium.

Cell culture and differentiation

The 3T3-L1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% calf serum and antibiotics (100 $\mu g \cdot ml^{-1}$ gentamycin and 100 $\mu g \cdot ml^{-1}$ penicillin-streptomycin). To induce differentiation, 2-day post-confluent 3T3-L1 cells were incubated in MDI induction media (DMEM containing 10% fetal bovine serum, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 1 μm dexamethasone and 1 $\mu g/ml$ of insulin) for 2 days. In some experiments, FTY720-p (1 μM) was added at the time of the induction of differentiation. Two days after MDI (DAY 2) the media was changed to insulin media.

Quantification of lipid content

Lipid content was quantified using AdipoRed Assay Reagent (Lonza, Verviers, Belgium) according to the manufacturer's instructions. In brief, preadipocytes grown in 24-well plates were incubated with MDI medium alone or medium + test compounds during the adipogenic phase and, on day 7. The wells were then filled with 300 μl PBS and 30 μl of Adipored reagent was added and incubated for 10 min at $37^{o}C$. Fluorescence was measured with an excitation and emission wavelength of 485 nm and 572 nm, respectively.

Adipolysis assay

Glycerol release was measured using the Adipolysis Assay Kit (Cayman Chemical) according to the manufacturer's instructions. Briefly, differentiated adipocytes in a 96-well plate were stimulated with FTY720-p for 24 h. After stimulation, the cell culture supernatants were collected from each well and stored until use at $-20^{o}C$. One hundred microliters of free glycerol assay reagent was added to 25 μl of each supernatant. After incubation for 15 min at room temperature, the absorbance was measured at 540 nm.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from 3T3-L1 cells treated with S1P using the Easy-spin™ total RNA extraction kit (iNtRON Biotechnology, Seoul, Korea). cDNA synthesis was carried out following the instructions of the Prime Script™ 1st strand cDNA synthesis kit (TaKaRa Bio, Tokyo, Japan). For qRT-PCR, 1 μl of gene primers with SYBR Green (Bio-Rad Laboratories, Hercules, CA) in 20 μl of reaction volume was applied. The sequences of the primers used for the

Real-time PCR were as follows:
PPARγ (forward 5'CGGAAGCCCTTTGGTGACTTTATG3', reverse 5'GCAGCAGGTTGTCTTGGATGTC3'), C/EBP-α (forward 5'CGGGAACGCAACAACATCGC3', reverse 5'TG TCCAGTTCACGGCTCAGC3'), Adiponectin (forward 5'TG ACGGCAGCACTGGCAAG3', reverse 5'TGATACTGGTCG TAGGTGAAGAGAAC3') ATGL (forward 5'GAGCTTCGCG TCACCAAC3', reverse 5'CACATCTCTCGGAGGACCA3'), HSL (forward 5'AGACCACATCGCCCACA3', reverse 5'CC TTTATTGTCAGCTTCTTCAAGG3'), Perilipin (forward 5'C ACTCTCTGGCCATGTGGA3', reverse 5'AGAGGCTGCCA GGTTGTG3') and β-actin (forward 5'TGAGAGGGAAATCG TGCGTGAC3', reverse 5'GCTCGTTGCCAATAGTGATGA CC3').

All reactions with iTaq SYBR Green Supermix (Bio-Rad Laboratories) were performed on the CFX96 real-time PCR detection system (Bio-Rad Laboratories).

Western blot

The 3T3-L1 cells were lysed in a lysis buffer (25 mM HEPES; pH 7.4, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl$_2$, 0.1 mM dithiothreitol and protease inhibitor mixture). Proteins were electrophoretically resolved by 8-15% so-dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting was performed as pre-viously described (Moon *et al.*, 2011). Images were cap-tured using the Fusion FX7 acquisition system (Vilbert Lourmat, Eberhardzell, Germany) (Seo *et al.*, 2012). The antibodies used for immunoblotting were p-Akt (Ser 473) (Epitomics, Burlingame, CA), p-GSK3α/β (Tyr279/216) (Santa Cruz Biotechnology, Santa Cruz, CA), p-HSL (Ser 563) (Cell Signaling Technology, Beverly, MA), p-HSL (Ser 565) (Cell Signaling Technology) and β-actin (Sigma-Aldrich, St. Louis, MO).

Statistical evaluation

All data are expressed as the mean $\pm$ SEM, and the data were compared using the Student's *t*-test and the ANOVA Duncan test with the SAS statistical package. The results were considered significant for values of *$P < 0.05$ or **$P < 0.01$.

Acknowledgements

References

Anthonsen MW, Rönnstrand L, Wernstedt C, Degerman E, Holm C. Identification of Novel Phosphorylation Sites in Hormone-sensitive Lipase That Are Phosphorylated in Response to Isoproterenol and Govern Activation Properties *in vitro*. J Biol Chem 1998;273:215-21

Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 2005;19: 471-82

Bézaire V, Mairal A, Anesia R, Lefort C, Langin D. Chronic TNFα and cAMP pre-treatment of human adipocytes alter HSL, ATGL and perilipin to regulate basal and stimulated lipolysis. FEBS lett 2009;583:3045-9

Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4: 1019-25

Chakraborty A, Koldobskiy MA, Bello NT, Maxwell M, Potter JJ, Juluri KR, Maag D, Kim S, Huang AS, Dailey MJ, Saleh M, Snowman AM, Moran TH, Mezey E, Snyder SH. Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell 2010;143:897-910

Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther 2005;108:308-19

Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-9

Daval M, Foufelle F, Ferré P. Functions of AMP-activated protein kinase in adipose tissue. J Physiol 2006;574:55-62

Dircks L, Sul HS. Acyltransferases of de novo glycer-ophospholipid biosynthesis. Prog Lipid Res 1999;38:461-79

Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS. Regulation of lipolysis in adipocytes. Annu Rev Nutr 2007;27:79-101

Funai K, Parkington JD, Carambula S, Fielding RA. Age-associated decrease in contraction-induced activation of downstream targets of Akt/mTor signaling in skeletal muscle. Am J Physiol Regul Integr Comp Physiol 2006;290: R1080-6

Gaidhu MP, Anthony NM, Patel P, Hawke TJ, Ceddia RB. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am J Physiol Cell Physiol 2010;298:C961-71

Garton AJ, Campbell DG, Carling D, Hardie DG, Colbran RJ, Yeaman SJ. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur J Biochem 1989;179:249-54

Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998;78:783-809

Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9: 139-50

Hertzel AV, Smith LA, Berg AH, Cline GW, Shulman GI, Scherer PE, Bernlohr DA. Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am J Physiol Endocrinol Metab 2006;290:E814-23

Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, Hamilton JA, Ouchi N, LeBrasseur NK, Walsh K. Fast/Glycolytic Muscle Fiber Growth Reduces Fat Mass and Improves Metabolic Parameters in Obese Mice. Cell Metab

2008;7:159-72

Jaworski K, Sarkadi-Nagy E, Duncan RE, Ahmadian M, Sul HS. Regulation of triglyceride metabolism. IV. Hormonal regulation of lipolysis in adipose tissue. Am J Physiol Gastrointest Liver Physiol 2007;293:G1-4

Jaworski K, Ahmadian M, Duncan RE, Sarkadi-Nagy E, Varady KA, Hellerstein MK, Lee HY, Samuel VT, Shulman GI, Kim KH, de Val S, Kang C, Sul HS. AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med 2009;15:159-68

Jocken JW, Blaak EE. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol Behav 2008;94:219-30

Kaidanovich O, Eldar-Finkelman H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets 2002;6:555-61

Kendall MR, Hupfeld CJ. FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice. Diabetes Obes Metab 2008;10:802-5

Kihara A, Igarashi Y. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta 2008; 1781:496-502

Kiuchi M, Adachi K, Kohara T, Minoguchi M, Hanano T, Aoki Y, Mishina T, Arita M, Nakao N, Ohtsuki M, Hoshino Y, Teshima K, Chiba K, Sasaki S, Fujita T. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1, 3-diols and 2-aminoethanols. J Med Chem 2000;43:2946-61

Lasa A, Schweiger M, Kotzbeck P, Churruca I, Simón E, Zechner R, Portillo MdP. Resveratrol regulates lipolysis *via* adipose triglyceride lipase. J Nutr Biochem 2012;23:379-84

Lee H, Lee YJ, Choi H, Ko EH, Kim JW. Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion. J Biol Chem 2009;284:10601-9

Lucas S, Tavernier G, Tiraby C, Mairal A, Langin D. Expression of human hormone-sensitive lipase in white adipose tissue of transgenic mice increases lipase activity but does not enhance *in vitro* lipolysis. J Lipid Res 2003;44: 154-63

Mansoor M, Melendez AJ. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine. Rev Recent Clin Trials 2008;3:62-9

Martinez-Botas J, Anderson JB, Tessier D, Lapillonne A, Chang BH, Quast MJ, Gorenstein D, Chen KH, Chan L. Absence of perilipin results in leanness and reverses obesity in Lepr (db/db) mice. Nat Genet 2000;26:474-9

Miyoshi H, Souza SC, Zhang HH, Strissel KJ, Christoffolete MA, Kovsan J, Rudich A, Kraemer FB, Bianco AC, Obin MS, Greenberg AS. Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis *via* phosphorylation-dependent and -independent mechanisms. J Biol Chem 2006;281:15837-44

Moon MH, Jeong JK, Seo JS, Seol JW, Lee YJ, Xue M, Jackson CJ, Park SY. Bisphosphonate enhances TRAIL

sensitivity to human osteosarcoma cells *via* death receptor 5 upregulation. Exp Mol Med 2011;43:138-45

Moreno-Navarrete JM, Ortega FJ, Ricart W, Fernandez-Real JM. Lactoferrin increases (172Thr)AMPK phosphorylation and insulin-induced (p473Ser)AKT while impairing adipocyte differentiation. Int J Obes (Lond) 2009;33:991-1000

Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med 2010;10:34

Nofer J-R, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EAL. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115:501-8

Ntambi JM, Kim Y. Adipocyte differentiation and gene expression. J Nutr 2000;130:3122S-6S

Pinto Lde F, Compri CM, Fornari JV, Bartchewsky W, Cintra DE, Trevisan M, Carvalho Pde O, Ribeiro ML, Velloso LA, Saad MJ, Pedrazzoli J, Jr., Gambero A. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int 2010;30:603-10

Rayalam S, Della-Fera MA, Baile CA. Phytochemicals and regulation of the adipocyte life cycle. J Nutr Biochem 2008;19: 717-26

Roden M. How Free Fatty Acids Inhibit Glucose Utilization in Human Skeletal Muscle. Physiology 2004;19:92-6

Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD, Glass DJ. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI (3)K/Akt/mTOR and PI (3)K/Akt/GSK3 pathways. Nat Cell Biol 2001;3:1009-13

Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006;7:885-96

Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, MacDougald OA. Inhibition of adipogenesis by wnt signaling. Science 2000;289:950-3

Sawada T, Miyoshi H, Shimada K, Suzuki A, Okamatsu-Ogura Y, Perfield JW, II, Kondo T, Nagai S, Shimizu C, Yoshioka N, Greenberg AS, Kimura K, Koike T. Perilipin overexpression in white adipose tissue induces a brown fat-like phenotype. PLoS One 2010;5:e14006

Seo JS, Moon MH, Jeong JK, Seol JW, Lee YJ, Park BH, Park SY. SIRT1, a histone deacetylase, regulates prion protein-induced neuronal cell death. Neurobiol Aging 2012;33: 1110-20

Shao J, Yamashita H, Qiao L, Friedman J. Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. J Endocrinol 2000;167:107-15

Shen WJ, Patel S, Natu V, Kraemer FB. Mutational analysis of structural features of rat hormone-sensitive lipase. Biochemistry 1998;37:8973-9

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-801

Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4:397-407

Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365: 1333-46

Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008;60:181-95

Tang QQ, Gronborg M, Huang H, Kim JW, Otto TC, Pandey A, Lane MD. Sequential phosphorylation of CCAAT enhancer-binding protein beta by MAPK and glycogen synthase kinase 3beta is required for adipogenesis. Proc Natl Acad Sci USA 2005;102:9766-71

Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, Reitman ML, Deng CX, Li C, Kimmel AR, Londos C. Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 2001;98:6494-9

Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77: 289-312

Valentine WJ, Kiss GN, Liu J, E S, Gotoh M, Murakami-Murofushi K, Pham TC, Baker DL, Parrill AL, Lu X, Sun C, Bittman R, Pyne NJ, Tigyi G. (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity. Cell Signal 2010;22:1543-53

Vingtdeux V, Chandakkar P, Zhao H, Davies P, Marambaud P. Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med 2011;17:1022-30

Wakabayashi K, Okamura M, Tsutsumi S, Nishikawa NS, Tanaka T, Sakakibara I, Kitakami J, Ihara S, Hashimoto Y, Hamakubo T, Kodama T, Aburatani H, Sakai J. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets the histone modification enzyme PR-Set7/Setd8 gene and regulates adipogenesis through a positive feedback loop. Mol Cell Biol 2009;29:3544-55

Xing Y, Yan F, Liu Y, Zhao Y. Matrine inhibits 3T3-L1 preadipocyte differentiation associated with suppression of ERK1/2 phosphorylation. Biochem Biophys Res Commun 2010;396:691-5

Yin W, Mu J, Birnbaum MJ. Role of AMP-activated Protein Kinase in Cyclic AMP-dependent Lipolysis In 3T3-L1 Adipocytes. J Biol Chem 2003;278: 43074-80

Zhou L, Wang X, Yang Y, Wu L, Li F, Zhang R, Yuan G, Wang N, Chen M, Ning G. Berberine attenuates cAMP-induced lipolysis *via* reducing the inhibition of phosphodiesterase in 3T3-L1 adipocytes. Biochim Biophys Acta 2011;1812: 527-35

Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 2004;306:1383-6